Allegro Diagnostics Presents Results from AEGIS I Clinical Trial

On October 23rd MBBP client Allegro Diagnostics, Inc. announced positive results from the AEGIS I (Airway Epithelium Gene Expression In the Diagnosis of Lung Cancer) clinical trial. The trial was meant to test the diagnostic accuracy of BronchoGen™, Allegro's lead genomic test intended to bring early detection to the standard of care for lung cancer. Allegro Diagnostics' …

BU Names Allegro Founder 2011 Innovator of the Year

On July 19th, MBBP client Boston University hosted its second annual Tech, Drugs and Rock & Roll event which 500 industry professionals, entrepreneurs and BU community members attended for an evening of food, drinks, music and technology. BU provost and chief academic officer Jean Morrison also presented the 2011 Innovator of the Year award to School …

Allegro Diagnostics Enters License Agreement with Boston University

On June 29th, MBBP client Allegro Diagnostics, Inc. announced that it has entered into an exclusive license agreement with MBBP client Boston University and the University of Utah Foundation for intellectual property related to Allegro Diagnostics' molecular testing platform which utilizes a genomic biomarker to detect early signs of lung cancer. Mike Webb, President and CEO …

Allegro Diagnostic to Launch Lung Cancer Test by 2011

MBBP Client Allegro Diagnostics will begin marketing a "microarray-based test" for early-stage lung cancer. Allegro CEO Dan Rippy intends to offer a test called BronchoGen as a unique service through its clinical laboratory. BronchoGen is an 80-gene biomarker assay that can detect and rule out the presence of cancer cells. This screening will complement bronchoscopy, …